Products for Research Use Only

Avotaciclib (hydrochloride)

CAT: 0804-HY-137432B-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-137432B-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Avotaciclib (BEY1107) hydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib hydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib hydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer[1][2].
Product Name Alternative
BEY1107 (hydrochloride)
UNSPSC
12352005
Target
Apoptosis; CDK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/avotaciclib-hydrochloride.html
Purity
99.75
Solubility
DMSO : 14.29 mg/mL (ultrasonic; warming; heat to 60°C)
Smiles
OC1=C(N=C(C=C1)C2=NC(N)=NC=C2)C3=CC=NC(N)=N3.Cl
Molecular Formula
C13H12ClN7O
Molecular Weight
317.73
References & Citations
[1]Xie Z, et al. Lessons Learned from Past Cyclin-Dependent Kinase Drug Discovery Efforts. J Med Chem. 2022 May 12;65 (9) :6356-6389.|[2]Zhang L, et al. Suppression of cyclin-dependent kinase 1 synergizes with checkpoint kinase 2 inhibitor to promote death of non-small cell lung cancer cells with radiotherapeutic resistance. Journal of Radiation Research and Applied Sciences, 2024, 17 (2) : 100900.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Scientific Category
Reference compound1
Clinical Information
Phase 2
Isoform
CDK1
Citation 01
Clin Sci. 2025 Oct 22;139 (20) :1163-1185.|Cancer Cell Int. 2024 Dec 19;24 (1) :409.|J Radiat Res Appl Sci. 2024Jun, 17, 2, 100900.